CompletedNot Applicable

Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

Japan67 participantsStarted 2023-06-19

Plain-language summary

To understand the incidence of ADRs of Calquence capsules 100 mg (acalabrutinib) used in patients with previously untreated chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma (SLL)) in the post-marketing setting under actual use

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Patients with previously untreated chronic lymphocytic leukaemia (including small lymphocytic lymphoma) who are treated with Calquence for the first time will be enrolled in the study after the approval date of the sJNDA for the additional indication. \- Exclusion Criteria: None \-

What they're measuring

Incidence of ADRs

Timeframe: 24 weeks

Trial details

NCT IDNCT05665374

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-08-20

View on ClinicalTrials.gov More Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma) trials